In terms of antihypertensive therapy, angiotensin converting enzyme 2 (ACE2) may genuinely protect against severe respiratory infections by converting angiotensin II to angiotensin with significant anti-inflammatory properties, so an angiotensin converting enzyme inhibitors (ACEI) that results in increased ACE2 expression may really be beneficial, using ACEI or angiotensin II receptor blockers (ARBs) may benefit COVID-19 outcomes and positively modulate its outcomes, the recent meta-analyses further support the role of ACEIs and ARBs in disease progression beneficial effect (25). The gene discussed is ACE; the disease is COVID-19.